Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Redhill Biopharma (RDHL) ADR

Sell:$7.90 Buy:$7.91 Change: $0.47 (5.56%)
Market closed |  Prices as at close on 14 August 2020 | Switch to live prices |
Sell:$7.90
Buy:$7.91
Change: $0.47 (5.56%)
Deal now Deal for just £11.95 per trade in a Fund and Share Account
Market closed |  Prices as at close on 14 August 2020 | Switch to live prices |
Sell:$7.90
Buy:$7.91
Change: $0.47 (5.56%)
Market closed |  Prices as at close on 14 August 2020 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Fund and Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

RedHill Biopharma Ltd. is an Israel-based specialty biopharmaceutical company, primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases. The Company promotes the gastrointestinal drug Aemcolo in the United States (U.S.). Its key clinical late-stage development programs include: RHB-104, with positive results from a first Phase 3 study for Crohn's disease; RHB-204, with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) infections; RHB-102 (Bekinda), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; ABC294640 (Yeliva), RHB-106, and RHB-107.

Contact details

Address:
21 Ha'arba'a St.
TEL AVIV-YAFO
6473921
Israel
Telephone:
+972 (3) 5413131
Website:
https://www.redhillbio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
RDHL
ISIN:
US7574681034
Market cap:
$316.37 million
Shares in issue:
352.70 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Dror Ben-Asher
    Chairman of the Board, Chief Executive Officer
  • Micha Ben Chorin
    Chief Financial Officer
  • Gilead Raday
    Chief Operating Officer
  • Reza Fathi
    Senior Vice President - Research & Development
  • Adi Frish
    Senior Vice President - Business Development and Licensing
  • Uri Aharon
    Chief Accounting Officer
  • Patricia Anderson
    Vice President - Regulatory Affairs
  • Aida Bibliowicz
    Vice President - Clinical Affairs Europe
  • Robert Gilkin
    Vice President of Market Access
  • Rob Jackson
    Vice President of Marketing

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Fund and Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.